Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.

C Nieder1, U Nestle, R Ketter

  • 1Department of Radiotherapy, University Hospital of Saarland, Homburg/Saar, Germany. cnied@hotmail.com

Radiation Oncology Investigations
|February 25, 1999
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing digital patient-reported outcomes in routine cancer care: barriers and facilitators.

ESMO real world data and digital oncology·2026
Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

[Neoadjuvant PD-1 and PD-L1 block with chemotherapy in borderline resectable and unresectable stage III NSCLC: paradigm shift or evidence-poor hype?]

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

Systematic reviews and quality assessment of patient-reported outcome measures for physical function in comparative effectiveness studies regarding acute postoperative pain after total knee arthroplasty-Do we need to start all over again?

European journal of pain (London, England)·2024
Same author

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Hyperfractionated radiotherapy (hf-rt) and accelerated-hyperfractionated radiotherapy (ahf-rt) did not improve survival for glioblastoma multiforme (gbm) patients. However, ahf-rt reduced treatment time without compromising survival or increasing toxicity.

Area of Science:

  • Radiation Oncology
  • Neuro-oncology
  • Clinical Trials

Background:

  • Hyperfractionated radiotherapy (hf-rt) and accelerated-hyperfractionated radiotherapy (ahf-rt) offer radiobiological advantages for glioblastoma multiforme (gbm) treatment.
  • These techniques allow for dose escalation or reduced treatment duration, potentially improving patient outcomes.

Purpose of the Study:

  • To prospectively evaluate the efficacy and toxicity of hf-rt and ahf-rt compared to conventionally fractionated radiotherapy (cf-rt) in gbm patients.
  • To determine if reduced treatment time with ahf-rt impacts survival or toxicity.

Main Methods:

  • A prospective study comparing cf-rt (60 Gy, 2 Gy/fraction, 6 weeks) with hf-rt (78 Gy, 1.3 Gy/fraction BID, 6 weeks) and ahf-rt (60 Gy, 1.5 Gy/fraction BID, 4 weeks).
  • No chemotherapy was administered. Entry criteria included age ≥17 years, supratentorial gbm diagnosis, and post-surgical status.

Related Experiment Videos

  • Patient groups were analyzed for survival, progression-free survival, clinical course, and toxicity.

    • Main Results:

    • No significant differences in median survival (7-10 months) or 1-year survival rates (19%-29%) were observed between cf-rt, hf-rt, and ahf-rt groups.
    • Progression-free survival, clinical course, and toxicity profiles were also comparable across the treatment arms.
    • Karnofsky performance status, age, and corticosteroid dose were identified as key prognostic factors.

    Conclusions:

    • Neither hf-rt nor ahf-rt demonstrated improved survival outcomes for gbm compared to cf-rt.
    • Accelerated-hyperfractionated radiotherapy (ahf-rt) successfully reduced treatment time without compromising survival or increasing toxicity.
    • Short radiotherapy courses, like ahf-rt, may be suitable for gbm patients not candidates for more aggressive investigational therapies.